Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Claire Verschraegen

Showing results (1-10 of 69) with videos related to

Pageof 7
Sort By:
Cancer Management and Research|February 21, 2012
The monoclonal antibody to cytotoxic T lymphocyte antigen 4, ipilimumab, in the treatment of melanomaClaire Verschraegen
Drugs|November 1, 2011
Systemic management strategies for metastatic soft tissue sarcomaSujana Movva, Claire Verschraegen
Expert Opinion on Biological Therapy|February 25, 2009
The monoclonal antibody to cytotoxic T lymphocyte antigen 4, ipilimumab (MDX-010), a novel treatment strategy in cancer managementSujana Movva, Claire Verschraegen
Hematology/Oncology Clinics of North America|April 24, 2012
Topoisomerase 1 inhibitors and cancer therapyJulia Moukharskaya, Claire Verschraegen
Journal of the National Cancer Institute|January 22, 2004
Breast-conserving surgery with or without radiotherapy: pooled-analysis for risks of ipsilateral breast tumor recurrence and mortalityVincent Vinh-Hung, Claire Verschraegen
Current Opinion in Oncology|May 18, 2010
Locally advanced cervical cancer: what is the standard of care?Zeina Al-Mansour, Claire Verschraegen
Cancers|February 27, 2026
Clinical Importance of Molecular Biomarkers in Pleural MesotheliomaLogan Roof, Kenna Koehler, Claire Verschraegen
Cancers|November 11, 2022
Recent Advances in Immunotherapy for Patients with Head and Neck Cutaneous Squamous Cell CarcinomaAdam Khorasanchi, Richard Wu, Kari Kendra, et al.
Oncogene|March 10, 2004
Cyclin E deregulation alters the biologic properties of ovarian cancer cellsIsabelle Bedrosian, Karen H Lu, Claire Verschraegen, et al.
Cancer|May 20, 2009
Novel chemotherapy approaches for cervical cancerSujana Movva, Lorna Rodriguez, Hugo Arias-Pulido, et al.
Pageof 7

Showing results (1-10 of 69) with videos related to

Sort By:
Pageof 7
Cancer Management and Research|February 21, 2012
The monoclonal antibody to cytotoxic T lymphocyte antigen 4, ipilimumab, in the treatment of melanomaClaire Verschraegen
Drugs|November 1, 2011
Systemic management strategies for metastatic soft tissue sarcomaSujana Movva, Claire Verschraegen
Expert Opinion on Biological Therapy|February 25, 2009
The monoclonal antibody to cytotoxic T lymphocyte antigen 4, ipilimumab (MDX-010), a novel treatment strategy in cancer managementSujana Movva, Claire Verschraegen
Hematology/Oncology Clinics of North America|April 24, 2012
Topoisomerase 1 inhibitors and cancer therapyJulia Moukharskaya, Claire Verschraegen
Journal of the National Cancer Institute|January 22, 2004
Breast-conserving surgery with or without radiotherapy: pooled-analysis for risks of ipsilateral breast tumor recurrence and mortalityVincent Vinh-Hung, Claire Verschraegen
Current Opinion in Oncology|May 18, 2010
Locally advanced cervical cancer: what is the standard of care?Zeina Al-Mansour, Claire Verschraegen
Cancers|February 27, 2026
Clinical Importance of Molecular Biomarkers in Pleural MesotheliomaLogan Roof, Kenna Koehler, Claire Verschraegen
Cancers|November 11, 2022
Recent Advances in Immunotherapy for Patients with Head and Neck Cutaneous Squamous Cell CarcinomaAdam Khorasanchi, Richard Wu, Kari Kendra, et al.
Oncogene|March 10, 2004
Cyclin E deregulation alters the biologic properties of ovarian cancer cellsIsabelle Bedrosian, Karen H Lu, Claire Verschraegen, et al.
Cancer|May 20, 2009
Novel chemotherapy approaches for cervical cancerSujana Movva, Lorna Rodriguez, Hugo Arias-Pulido, et al.
Pageof 7